NOVARTIS ANGIOTENSIN II ANTAGONIST DIOVAN TO BE LAUNCHED IN SECOND QUARTER 1997; LABELING ON DRUG INTERACTIONS, EFFICACY IN BLACKS DIFFERS FROM MERCK's COZAAR
Executive Summary
Novartis' Diovan (valsartan) will begin competing with Merck's Cozaar (losartan) in the angiotensin II antagonist antihypertensive market in the second quarter of 1997.